Cargando…

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma

Immune checkpoint inhibitors (ICI) are a standard in cancer therapy, but few patients respond to the treatment. The aim of the present study was the determination of immunological markers for monitoring response to ICI. The present study included 74 patients receiving ICI in subsequent [group 1; non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Musaelyan, Aram A., Lapin, Sergey V., Urtenova, Margarita A., Odintsova, Svetlana V., Chistyakov, Ivan V., Ulitin, Andrey M., Akopov, Andrey L., Orlov, Sergey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366266/ https://www.ncbi.nlm.nih.gov/pubmed/35978940 http://dx.doi.org/10.3892/etm.2022.11495

Ejemplares similares

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Ultrafast signatures of magnetic inhomogeneity in Pd(1−)(x)Fe(x) (x ≤ 0.08) epitaxial thin films
por: Petrov, Andrey V, et al.
Publicado: (2022)

Anti−PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1
por: Cassol, Clarissa, et al.
Publicado: (2019)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab
por: Orlov, Sergey V., et al.
Publicado: (2020)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells
por: Martins, Christina, et al.
Publicado: (2022)

Pd Single-Atom Sites on the Surface of PdAu Nanoparticles: A DFT-Based Topological Search for Suitable Compositions
por: Mamatkulov, Mikhail, et al.
Publicado: (2021)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Nanostructured Zr-Pd Metallic Glass Thin Film for Biochemical Applications
por: Ketov, Sergey V., et al.
Publicado: (2015)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation
por: Linnerbauer, Mathias, et al.
Publicado: (2023)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model
por: Zhang, Xue, et al.
Publicado: (2020)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
por: Eichhorn, Florian, et al.
Publicado: (2021)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

PD-L1(+) lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients
por: Raniszewska, A., et al.
Publicado: (2020)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2o57etdh7n4vu1u4lna2304amr